A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: A 12-week, randomized, masked-evaluator multicenter study

PURPOSE: To compare the intraocular pressure (IOP), lowering effect and safety of latanoprost, bimatoprost, and travoprost in patients with open,angle glaucoma (OAG) or ocular hypertension (OH). DESIGN: Interventional study. METHODS: This 12-week, randomized, parallel-group study was conducted at 45 US sites. Previously treated patients with OAG or OH and an IOP greater than or equal to23 mm Hg in one or both eyes after washout received either latano, prost 0.005%, bimatoprost 0.03%, or travoprost 0.004% once daily in the evening. At baseline and after 6 and 12 weeks of therapy, masked evaluators measured IOP in triplicate at 8:00 Am, 12 noon, 4:00 Pm, and 8:00 Pm, and masked investigators graded conjunctival hyperemia before the 8:00 Am IOP measurement. The primary efficacy outcome measure was change between baseline and Week 12 in the 8:00 AM IOP (time of peak drug effect). RESULTS: In all, 410 of 411 randomized patients were included in intent,to-treat analyses (latanoprost, 136; bimatoprost, 136; travoprost, 138). Baseline mean 8:00 Am IOP levels were. similar (P = .772); by week 12, reductions were observed in all 3 groups (P < .001 for each). Adjusted (ANCOVA) reductions in mean IOP at 8:00 AM were similar (P = .128) as were those at 12 noon, 4:00 Pm, and 8:00 Pm. Fewer latanoprost,treated patients reported ocular adverse events (P < .001, latanoprost vs bimatoprost), fewer reported hyperemia (P = .001, latanoprost vs himatoprost), and average hyper, emia scores were lower at week 12. (P = .001, latanoprost vs himatoprost). CONCLUSIONS: Latanoprost, bimatoprost, and travoprost were comparable in their ability to reduce IOP in OAG and OH patients. Latanoprost exhibited greater ocular tolerability. (C) 2003 by Elsevier Inc. All rights reserved.